IB Acquisition Highlights GNQ Alliance Amid Pending Merger

IB Acquisition Corp. ( (IBAC) ) has provided an announcement.

On March 13, 2026, GNQ Insilico Inc. signed a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company to collaborate on sales, marketing, development, and alliance projects that advance AI-driven drug discovery and precision medicine solutions. The non-exclusive, global alliance, initially running for two years with an option to extend, will see GNQ integrate its proprietary AI platforms with the partner’s consulting, cloud, and quantum computing services to jointly develop business plans, pursue qualified customer leads, and deliver combined offerings across the healthcare and life sciences ecosystem.

The announcement comes as IB Acquisition Corp. pursues a proposed business combination with GNQ, with IB Acquisition preparing to file a registration statement and proxy materials with the U.S. Securities and Exchange Commission for shareholder consideration of the transaction. The GNQ partnership is poised to enhance the target company’s commercial reach and technological depth, potentially increasing the strategic appeal and growth prospects of the combined entity for investors and other stakeholders in the healthcare and life sciences technology space.

More about IB Acquisition Corp.

IB Acquisition Corp. is a special purpose acquisition company pursuing a business combination with GNQ Insilico Inc., an artificial intelligence-focused firm developing AI-driven drug discovery and precision medicine solutions for the healthcare and life sciences markets. GNQ leverages proprietary AI platforms, delivered alongside major technology partners’ cloud, consulting, and advanced computing capabilities, to serve pharmaceutical, biotech, and broader healthcare clients worldwide.

Average Trading Volume: 6,128

Technical Sentiment Signal: Strong Buy

Learn more about IBAC stock on TipRanks’ Stock Analysis page.